Artiva Biotherapeutics (NASDAQ:ARTV) Director Acquires $412,776.81 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 41,319 shares of the stock in a transaction on Friday, July 24th. The stock was acquired at an average cost of $9.99 per share, with a total value of $412,776.81. Following the acquisition, the director owned 17,283,802 shares of the company’s stock, valued at approximately $172,665,181.98. This represents a 0.24% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, July 23rd, Ra Capital Management, L.P. acquired 59,880 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.96 per share, for a total transaction of $596,404.80.
• On Wednesday, July 22nd, Ra Capital Management, L.P. acquired 84,124 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.93 per share, with a total value of $835,351.32.
• On Tuesday, July 21st, Ra Capital Management, L.P. acquired 120,582 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.97 per share, with a total value of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. bought 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.88 per share, for a total transaction of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.

Artiva Biotherapeutics Price Performance

Shares of ARTV opened at $10.43 on Friday. The company’s fifty day moving average price is $8.96 and its 200-day moving average price is $7.49. Artiva Biotherapeutics, Inc. has a 1-year low of $2.22 and a 1-year high of $14.53. The firm has a market capitalization of $257.80 million, a PE ratio of -2.95 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Prelude Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $41,000. Bank of America Corp DE lifted its stake in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after buying an additional 11,190 shares in the last quarter. Bridgeway Capital Management LLC purchased a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $53,000. Qube Research & Technologies Ltd acquired a new stake in Artiva Biotherapeutics in the 2nd quarter worth about $58,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the 2nd quarter worth about $67,000.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Wedbush upped their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Finally, Wall Street Zen downgraded shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.